Gender and pramipexole effects on levodopa pharmacokinetics and pharmacodynamics

Katie Kompoliti; C. H. Adler; R. Raman; J. H. Pincus; M. T. Leibowitz; J. J. Ferry; L. Blasucci; J. N. Caviness; S. Leurgans; W. M. Chase; L. C. Yones; E. Tan; P. Carvey; C. G. Goetz

doi:10.1212/WNL.58.9.1418

Gender and pramipexole effects on levodopa pharmacokinetics and pharmacodynamics

Katie Kompoliti, C. H. Adler, R. Raman, J. H. Pincus, M. T. Leibowitz, J. J. Ferry, L. Blasucci, J. N. Caviness, S. Leurgans, W. M. Chase, L. C. Yones, E. Tan, P. Carvey, C. G. Goetz

Neurology

Research output: Contribution to journal › Article › peer-review

47 Scopus citations

Abstract

The authors studied the pharmacokinetics of levodopa (LD) with and without pramipexole (PPX) in men and postmenopausal women with PD. Patients on stable dose of carbidopa/LD were randomized to receive escalating doses of placebo or PPX over 7 weeks. LD and PPX pharmacokinetics were performed after a single test dose 25/100 of carbidopa/LD, before initiation of PPX or placebo, at 1.5 mg/d and 4.5 mg/d of PPX or placebo. Compared to men, women had greater LD bioavailability. PPX did not alter LD bioavailability, and PPX pharmacokinetics were equivalent in men and women.

Original language	English (US)
Pages (from-to)	1418-1422
Number of pages	5
Journal	Neurology
Volume	58
Issue number	9
DOIs	https://doi.org/10.1212/WNL.58.9.1418
State	Published - May 14 2002

ASJC Scopus subject areas

Clinical Neurology

Access to Document

10.1212/WNL.58.9.1418

Cite this

@article{3bd98f7a244b40328e11d08c354da672,

title = "Gender and pramipexole effects on levodopa pharmacokinetics and pharmacodynamics",

abstract = "The authors studied the pharmacokinetics of levodopa (LD) with and without pramipexole (PPX) in men and postmenopausal women with PD. Patients on stable dose of carbidopa/LD were randomized to receive escalating doses of placebo or PPX over 7 weeks. LD and PPX pharmacokinetics were performed after a single test dose 25/100 of carbidopa/LD, before initiation of PPX or placebo, at 1.5 mg/d and 4.5 mg/d of PPX or placebo. Compared to men, women had greater LD bioavailability. PPX did not alter LD bioavailability, and PPX pharmacokinetics were equivalent in men and women.",

author = "Katie Kompoliti and Adler, {C. H.} and R. Raman and Pincus, {J. H.} and Leibowitz, {M. T.} and Ferry, {J. J.} and L. Blasucci and Caviness, {J. N.} and S. Leurgans and Chase, {W. M.} and Yones, {L. C.} and E. Tan and P. Carvey and Goetz, {C. G.}",

year = "2002",

month = may,

day = "14",

doi = "10.1212/WNL.58.9.1418",

language = "English (US)",

volume = "58",

pages = "1418--1422",

journal = "Neurology",

issn = "0028-3878",

publisher = "Lippincott Williams and Wilkins",

number = "9",

}

TY - JOUR

T1 - Gender and pramipexole effects on levodopa pharmacokinetics and pharmacodynamics

AU - Kompoliti, Katie

AU - Adler, C. H.

AU - Raman, R.

AU - Pincus, J. H.

AU - Leibowitz, M. T.

AU - Ferry, J. J.

AU - Blasucci, L.

AU - Caviness, J. N.

AU - Leurgans, S.

AU - Chase, W. M.

AU - Yones, L. C.

AU - Tan, E.

AU - Carvey, P.

AU - Goetz, C. G.

PY - 2002/5/14

Y1 - 2002/5/14

N2 - The authors studied the pharmacokinetics of levodopa (LD) with and without pramipexole (PPX) in men and postmenopausal women with PD. Patients on stable dose of carbidopa/LD were randomized to receive escalating doses of placebo or PPX over 7 weeks. LD and PPX pharmacokinetics were performed after a single test dose 25/100 of carbidopa/LD, before initiation of PPX or placebo, at 1.5 mg/d and 4.5 mg/d of PPX or placebo. Compared to men, women had greater LD bioavailability. PPX did not alter LD bioavailability, and PPX pharmacokinetics were equivalent in men and women.

AB - The authors studied the pharmacokinetics of levodopa (LD) with and without pramipexole (PPX) in men and postmenopausal women with PD. Patients on stable dose of carbidopa/LD were randomized to receive escalating doses of placebo or PPX over 7 weeks. LD and PPX pharmacokinetics were performed after a single test dose 25/100 of carbidopa/LD, before initiation of PPX or placebo, at 1.5 mg/d and 4.5 mg/d of PPX or placebo. Compared to men, women had greater LD bioavailability. PPX did not alter LD bioavailability, and PPX pharmacokinetics were equivalent in men and women.

UR - http://www.scopus.com/inward/record.url?scp=0037076466&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037076466&partnerID=8YFLogxK

U2 - 10.1212/WNL.58.9.1418

DO - 10.1212/WNL.58.9.1418

M3 - Article

C2 - 12011296

AN - SCOPUS:0037076466

SN - 0028-3878

VL - 58

SP - 1418

EP - 1422

JO - Neurology

JF - Neurology

IS - 9

ER -

Gender and pramipexole effects on levodopa pharmacokinetics and pharmacodynamics

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this